Article

Etiology and management of therapy-related myeloid leukemia.

University of Chicago, MC-2115, 5841 S. Maryland Avenue, Chicago, IL 60637, USA.
Hematology (Impact Factor: 2.86). 02/2007; DOI: 10.1182/asheducation-2007.1.453
Source: PubMed

ABSTRACT The diagnosis of therapy-related myeloid leukemia (t-MDS/t-AML) identifies a group of high-risk patients with multiple and varied poor prognostic features. These neoplasms are thought to be the direct consequence of mutational events induced by cytotoxic therapy. Their outcomes have historically been poor compared with those of people who develop acute myeloid leukemia (AML) de novo. The question arises whether a diagnosis of t-AML per se indicates a poor prognosis, or whether their bad outcomes result from other clinical and biologic characteristics. Because of lingering damage from prior cytotoxic therapy and, in some cases, the persistence of their primary disorder, patients with t-AML are often poor candidates for intensive AML therapy. The spectrum of cytogenetic abnormalities in t-AML is similar to de novo AML, but the frequency of unfavorable cytogenetics, such as a complex karyotype or deletion or loss of chromosomes 5 and/or 7, is higher in t-AML. Survival varies according to cytogenetic risk group, with better outcomes observed in patients with t-AML with favorable-risk karyotypes. Treatment recommendations should be based on performance status and karyotype. Patients with t-AML should be enrolled on front-line chemotherapy trials, appropriate for de novo AML patients with similar disease characteristics. Allogeneic hematopoietic cell transplantation can cure some patients with t-AML. Most important , the molecular and genetic differences that appear to determine the phenotype and the outcome of these patients need to be investigated further.

0 Followers
 · 
54 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Therapy-related leukemia is a well-documented complication of conventional therapy for cancer. Therapy-related acute myeloid leukemia (t-AML) is grouped along with therapy-related myelodysplastic syndrome (t-MDS) and therapy-related myelodysplastic syndrome/myeloproliferative neoplasms (t-MDS/MPN) as therapy-related myeloid neoplasms (t-MN) by the 2008 WHO classification system. Therapy-related myeloid neoplasms differ clinically from their de novo counterparts in terms of response to therapy, aggressiveness of disease, and associated poor prognosis.Occurrence of extramedullary myeloid sarcomas with bone marrow involvement has been shown to be a poor prognostic indicator for patients with t-MN. The karyotype of leukemic blasts has also been reported to have a significant impact in t-MN and may predict survival and outcomes in patients. The t(8;16)(p11.2;p13.3) is a rare, balanced translocation that is frequently associated with the M4/M5 subtype of de novo acute myeloid leukemia. It has also been reported in patients with t-MN, typically with poor outcomes. Here we report a case of t-MN with myeloid sarcoma and bone marrow involvement in an adult patient with a karyotype of 47,XY,t(8;16)(p11.2;p13.3),+21 after R-CHOP chemotherapy for follicular lymphoma.
    Cancer Genetics 10/2014; 207(10-12). DOI:10.1016/j.cancergen.2014.10.008 · 2.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aufgrund seiner hohen Effektivität in der Behandlung der schubförmig progressiven sowie sekundär progredienten Multiplen Sklerose (MS) hat Mitoxantron einen hohen Stellenwert in der Eskalationstherapie. Die therapieassoziierte akute Leukämie (,,therapy related acute leukemia“, TRAL) nach Mitoxantron-Applikation ist rezent in den Blickpunkt des Interesses gerückt.Der Fallbericht einer TRAL mit hämatologisch-onkologischer Differenzialdiagnostik wird aufgearbeitet und mögliche Risikofaktoren diskutiert. Die interdisziplinäre hämatologisch-onkologische sowie neurologische Entwicklung diagnostischer und therapeutischer Algorithmen bei unklarer Zytopenie unter Mitoxantron wird erörtert.Wir beschreiben den Fall eines 34-jährigen MS-Patienten mit einer TRAL nach einer kumulativen Gesamtdosis von 45 mg/m2 Körperoberfläche Mitoxantron. Der Patient verstarb an einer Endokarditis. TRAL sind seltene aber schwerwiegende Komplikationen einer Mitoxantron-Therapie, allerdings mit einer breiten Streuung der berichteten Inzidenz. In der Literatur sind bislang keine sicheren Risikofaktoren und Abhängigkeiten von Vortherapien und von Therapieschemata identifiziert. Engmaschige Laborkontrollen sowie frühzeitige Knochenmarkpunktionen sind bei Verdacht auf eine TRAL essenziell, da die TRAL prinzipiell kurativ therapierbar ist.Das Risiko einer TRAL ist bei der Indikationsstellung für eine Eskalationstherapie mit Mitoxantron zu berücksichtigen, wobei die exakte Inzidenz sowie Risikofaktoren (Dosierung, Therapieschema) noch unklar sind. Unter engmaschigem Monitoring sind die Risiken allerdings beherrschbar. Künftige Untersuchungen müssen auf die Identifizierung von Risikofaktoren von TRAL unter Mitoxantron-Therapie abzielen.
    Der Nervenarzt 01/2010; 81(12). · 0.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Survival following childhood neuroblastoma is improving with low rates of secondary myeloid neoplasms. We describe a 13-month-old male with intermediate risk neuroblastoma who developed an isolated scalp therapy-related myeloid sarcoma (t-MS). Developmental delays and two distinct malignancies prompted constitutional evaluation. Chromosomal microarray identified a 7.3 Mb deletion of 9q22.32 to 9q31.1. He remains in remission 11 months following hematopoietic cell transplant. Unusual presentations of rare diseases necessitate a multidisciplinary approach and adaptation of standardized protocols to accommodate increased risks imposed by genetic variants. Pediatr Blood Cancer © 2014 Wiley Periodicals, Inc.
    Pediatric Blood & Cancer 09/2014; 61(9). DOI:10.1002/pbc.25040 · 2.56 Impact Factor

Preview